mRNA Vaccine Development against Tropical Diseases
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "DNA and mRNA Vaccines".
Deadline for manuscript submissions: closed (28 February 2023) | Viewed by 4403
Special Issue Editor
Special Issue Information
Dear Colleagues,
At least one billion people are still affected by Tropical Diseases in Africa, Asia, and Latin America. Affecting the poorest areas in the regions, the most effective intervention to prevent infectious disease is vectorial control and improvements to sanitation, water quality, and hygiene, but these interventions are not enough. Vaccination is the most effective way to prevent infectious diseases. However, complex pathogens such as Plasmodium (Malaria), Trypanosoma cruzi (Chagas), Trypanosoma brucei (African Sleeping Sickness), Leishmania, Zika, and others have not been yet effectively tackled with conventional vaccines. mRNA vaccines for COVID-19 demonstrated how plasticity can accelerate the development of new vaccines for complex diseases.
We are pleased to announce this Special Issue on “mRNA Vaccine Development against Tropical Diseases”. The issue centers on (1) screening and identifying suitable vaccine candidates using novel in vitro techniques and assays, which allows for a better understanding of the biological and immunological complexities of pathogens, infection, and disease; (2) progress in nucleic acid delivery technology and how it improves vaccine potency and safety; and (3) the regulatory and manufacturer challenges to implementations in the regions (Asia, Africa, Latin America).
Dr. Cristina Poveda
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- mRNA vaccine
- Chagas disease
- tropical diseases
- immunology
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
